ZyVersa Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing drugs for chronic kidney disease and inflammatory diseases. The company is developing an injectable cholesterol efflux mediator, VAR 200, in clinical development for the treatment of kidney disease, an inflammasome ASC inhibitor, IC 100, for the treatment of inflammation, and is also conducting trials in patients with diabetic kidney disease. Based in Delaware.
Overview
Overview | |
|---|---|
Country | United States |
State | New Jersey |
Employees | 7 |
Founded | 2014 |
Financials | |
|---|---|
Market Capitalization | 4.09M |
Revenue | |
Operating Income | -105.99M |
Operating Margin | |
Net Income | -105.53M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4821 / 5373 |
Sector : Healthcare | 901 / 1144 |
Industry : Biotechnology | 464 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 5437 / 5565 |
Sector : Healthcare | 1112 / 1182 |
Industry : Biotechnology | 628 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4776 / 5436 |
Sector : Healthcare | 905 / 1164 |
Industry : Biotechnology | 473 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 5079 / 5330 |
Sector : Healthcare | 1094 / 1174 |
Industry : Biotechnology | 600 / 667 |